---
ticker: "BMED"
name: "iShares Health Innovation Active ETF"
url: "https://etf.net/etf/BMED"
grade: "C"
score: 42
graded_at: "2026-10-12"
category: "US Active Sector"
category_rank: "22 of 35"
methodology: "https://etf.net/methodology"
---

# BMED: iShares Health Innovation Active ETF

Grade **C**, Score 42 of 100. Rank 22 of 35 in US Active Sector.

Graded Oct 12, 2026.

## Grade pillars

| Pillar | Score | Category rank |
| --- | --- | --- |
| Cost | 32 | 24 of 35 |
| Mission | 73 | 5 of 9 |
| Risk | 57 | 10 of 35 |
| Tradability | 19 | 33 of 35 |
| Holdings | 79 | 6 of 35 |
| Durability | 59 | 14 of 35 |

## Top holdings

The fund holds 59 positions. These are the largest 30, by weight.

| # | Ticker | Name | Weight |
| --- | --- | --- | --- |
| 1 | MRNA | Moderna | 5.70% |
| 2 | GILD | Gilead Sciences | 5.54% |
| 3 | — | Blk Csh Fnd Treasury Sl Agency | 5.39% |
| 4 | DHR | Danaher | 5.18% |
| 5 | ABBV | AbbVie | 4.90% |
| 6 | TMO | Thermo Fisher Scientific Inc | 4.32% |
| 7 | JNJ | Johnson & Johnson | 4.14% |
| 8 | IQV | Iqvia Holdings Inc | 3.64% |
| 9 | WAT | Waters Corp | 3.63% |
| 10 | BIIB | Biogen | 3.54% |
| 11 | MTD | Mettler Toledo | 3.43% |
| 12 | VRTX | Vertex Pharmaceuticals | 3.28% |
| 13 | MRK | Merck & Co Inc | 3.12% |
| 14 | EW | Edwards Lifesciences | 2.94% |
| 15 | ROP.SW | Roche Ps Par AG | 2.67% |
| 16 | AMGN | Amgen Inc | 2.42% |
| 17 | DXCM | Dexcom Inc | 2.38% |
| 18 | ILMN | Illumina Inc | 2.27% |
| 19 | HALO | Halozyme Therapeutics | 2.04% |
| 20 | GMAB | Genmab Sponsored Adr | 1.95% |
| 21 | NOVN.SW | Novartis AG | 1.83% |
| 22 | ARGX | Argenx SE Adr | 1.66% |
| 23 | PFE | Pfizer | 1.52% |
| 24 | CRL | Charles River Laboratories Interna | 1.51% |
| 25 | 2269.HK | Wuxi Biologics Cayman | 1.45% |
| 26 | GH | Guardant Health | 1.42% |
| 27 | NBIX | Neurocrine Biosciences | 1.42% |
| 28 | ROIV | Roivant Sciences Ltd | 1.33% |
| 29 | CYTK | Cytokinetics | 1.32% |
| 30 | BMY | Bristol Myers Squibb | 1.32% |

Source: etf.net, https://etf.net/etf/BMED. Please cite the page URL.